Weekly shot shows promise for helping kids with dwarfism grow

NCT ID NCT05929807

ENROLLING_BY_INVITATION Disease control Sponsor: Ascendis Pharma Growth Disorders A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests a weekly injection called TransCon CNP in children and teens with achondroplasia, the most common form of dwarfism. The goal is to see if it is safe and helps improve growth over several years. Participants who completed a previous TransCon CNP trial can join this long-term extension, receiving the same dose until their bones stop growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TransCon CNP (a weekly injection of C-type natriuretic peptide)
What this could lead to: If successful, this treatment could help children with achondroplasia grow taller and improve bone development, potentially reducing some complications of the condition.
What could go wrong: This is an early-to-mid stage trial with no placebo group, so results may be less reliable. Possible side effects include injection site reactions and unknown long-term risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

achondroplasia Dwarfism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACHONDROPLASIA

Contacts and locations

Locations

Ascendis Investigational Site

Aurora, Colorado, 80045, United States
Ascendis Investigational Site

Wilmington, Delaware, 19803, United States
Ascendis Investigational Site

Saint Paul, Minnesota, 55102, United States
Ascendis Investigational Site

Houston, Texas, 77030, United States
Ascendis Investigational Site

Linz, 4020, Austria
Ascendis Investigational Site

Montreal, H3T 1C5, Canada
Ascendis Investigational Site

Berlin, 13353, Germany
Ascendis Investigational Site

Auckland, 1023, New Zealand
Ascendis Investigational Site

Coimbra, 3000-602, Portugal
Ascendis Investigational Site

Vitoria-Gasteiz, 1008, Spain
Ascendis Investigational Site

London, SE1 7EH, United Kingdom
Ascendis Pharma Investigational Site

Little Rock, Arkansas, 72202, United States
Ascendis Pharma Investigational Site

Columbia Falls, Montana, 65212, United States
Ascendis Pharma Investigational Site

Buffalo, New York, 14203, United States
Ascendis Pharma Investigational Site

Madison, Wisconsin, 53705, United States
Ascendis Pharma Investigational Site

Parkville, Victoria, 3052, Australia
Ascendis Pharma Investigational Site

Copenhagen, 2100, Denmark
Ascendis Pharma Investigational Site

Dublin, D01 YC76, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.